Department of Gastroenterology, Okayama University Hospital, Okayama, Japan.
Department of Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan.
Clin Gastroenterol Hepatol. 2022 May;20(5):1010-1018.e3. doi: 10.1016/j.cgh.2021.06.043. Epub 2021 Jul 2.
Endoscopic resection of nonampullary duodenal adenoma is often challenging, and its technique has not yet been standardized. To overcome the practical difficulty of conventional endoscopic mucosal resection, underwater endoscopic mucosal resection (UEMR) was recently developed; therefore, we investigated the effectiveness and safety of UEMR for nonampullary duodenal adenoma.
A multicenter, prospective cohort study was conducted at 21 institutions in Japan. We enrolled patients with no more than 2 nonampullary duodenal adenomas ≤20 mm in size, who were planned to undergo UEMR. After UEMR, follow-up endoscopies were scheduled at 2 and 12 months after the procedure, and biopsy specimens were taken from the post-UEMR scars. The primary endpoint was the proportion of patients with histologically proven nonrecurrence at follow-up endoscopy and biopsy.
A total of 155 patients with 166 lesions underwent UEMR. One patient with a non-neoplastic lesion in the resected specimen and 10 patients with 10 lesions who were lost to follow-up were excluded. Finally, 144 patients with 155 lesions who received all follow-up endoscopies were analyzed for the primary endpoint. The proportion of patients with proven nonrecurrence was 97.2% (n = 140 of 144; 95% confidence interval, 92.8%-99.1%) which exceeded the predefined threshold value (92%). Two cases of delayed bleeding (1.2%) occurred and they were successfully managed by clips. All recurrences were successfully treated by additional endoscopic treatment.
This multicenter, prospective cohort study demonstrated effectiveness and safety of UEMR for nonampullary duodenal adenomas ≤20 mm in size. (University Hospital Medical Network Clinical Trials Registry, Number: UMIN000030414).
内镜切除非壶腹十二指肠腺瘤常常具有挑战性,其技术尚未标准化。为克服传统内镜黏膜切除术的实际困难,最近开发了水下内镜黏膜切除术(UEMR);因此,我们研究了 UEMR 治疗非壶腹十二指肠腺瘤的有效性和安全性。
在日本的 21 家机构进行了一项多中心前瞻性队列研究。我们招募了计划行 UEMR 治疗、大小不超过 2 个、最大径不超过 20mm 的非壶腹十二指肠腺瘤数量不超过 2 个的患者。UEMR 后,在术后 2 个月和 12 个月进行随访内镜检查,并从 UEMR 后疤痕处取活检标本。主要终点是在随访内镜和活检中组织学证实无复发的患者比例。
共有 155 例 166 个病灶患者接受了 UEMR 治疗。1 例切除标本中为非肿瘤性病变的患者和 10 例失访的患者(10 个病灶)被排除。最终,144 例 155 个病灶患者接受了所有随访内镜检查,用于分析主要终点。无复发患者比例为 97.2%(n=140/144;95%置信区间,92.8%-99.1%),超过了预设的阈值(92%)。2 例(1.2%)发生延迟性出血,均通过夹闭成功治疗。所有复发均通过额外的内镜治疗成功治疗。
这项多中心前瞻性队列研究表明,UEMR 治疗大小不超过 20mm 的非壶腹十二指肠腺瘤是有效且安全的。(大学医院医疗网络临床试验注册处,编号:UMIN000030414)。